Respirator Protection Devices and Methods to Detect and Remove Toxic Gases from the Air - Cobinamide Encapsulated Silica-based Materials for Respirator Canisters
Adjustable Barricade Safety Rail System and Roof Bracket Assembly to Prevent Worker Falls
Wipes and Methods for Removal of Lead and Other Metal Contamination from Surfaces
Handwipe Disclosing Method for Detecting the Presence of Lead
2-substituted Pyridines and Their Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva
Naphthalene-containing Selective Inhibitors of BMP type 1 Receptors for the Treatment of Fibrodysplasia Ossificans Progressiva
Degrader Molecules for hRpn13Pru, PCLAF, RRM2 and Other KEN Box-containing Proteins
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for three small molecules that target hRpn13, an overexpressed protein in certain cancers.
Description of Technology:
Reverse Thiazine Kinase Inhibitors
Summary
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a class of novel aplithianine-derived small molecule analogs that compete with ATP for binding on a range of clinically relevant kinases including:
T Cell Receptors Targeting EGFR L858R mutation on HLA-A*11:01+ Tumors for Use as Research Tools
Tumor-specific mutated proteins can create neoepitopes, mutation-derived antigens that distinguish tumor cells from healthy cells, which are attractive targets for adoptive cell therapies. However, the process of precisely identifying the neoepitopes to target is complex and challenging. One method to identify such neoepitopes is Mass Spectrometry (MS) when used in conjunction with elution of peptides bound to a specific Human Leukocyte Antigen (HLA) allele.